Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
You may also be interested in...
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
BTK inhibitors are in late-stage development for multiple sclerosis, with Merck KgAA and Sanofi in the lead and Roche and Novartis close behind.
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.